# Standex International Corp: financial statements, quarterly SXI · NYSE · CIK 310354 · [Industrials](/sectors/industrials.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/sxi.md) · [Financials](/companies/sxi/financials.md) · [Filings](/companies/sxi/filings.md) · [Insiders](/companies/sxi/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sxi/financials.md?period=annual). ## Income statement | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [185](/filings/0001437749-24-032878.md) | [178](/filings/0001437749-25-002393.md) | [177](/filings/0001437749-25-014264.md) | [180 d](/filings/0001437749-26-027789.md) | [170](/filings/0001437749-25-032584.md) | [190](/filings/0001437749-26-002599.md) | [208](/filings/0001437749-26-014992.md) | [222 d](/filings/0001437749-26-027789.md) | [217](/filings/0001437749-25-032584.md) | [221](/filings/0001437749-26-002599.md) | [225](/filings/0001437749-26-014992.md) | [228 d](/filings/0001437749-26-027789.md) | | Cost of revenue | $m | [112](/filings/0001437749-24-032878.md) | [107](/filings/0001437749-25-002393.md) | [109](/filings/0001437749-25-014264.md) | [111 d](/filings/0001437749-26-027789.md) | [100](/filings/0001437749-25-032584.md) | [118](/filings/0001437749-26-002599.md) | [125](/filings/0001437749-26-014992.md) | [131 d](/filings/0001437749-26-027789.md) | [127](/filings/0001437749-25-032584.md) | [129](/filings/0001437749-26-002599.md) | [133](/filings/0001437749-26-014992.md) | [131 d](/filings/0001437749-26-027789.md) | | Gross profit | $m | [72.6](/filings/0001437749-24-032878.md) | [71.7](/filings/0001437749-25-002393.md) | [68.3](/filings/0001437749-25-014264.md) | [69.4 d](/filings/0001437749-26-027789.md) | [70.1](/filings/0001437749-25-032584.md) | [71.4](/filings/0001437749-26-002599.md) | [82.4](/filings/0001437749-26-014992.md) | [91.3 d](/filings/0001437749-26-027789.md) | [90.4](/filings/0001437749-25-032584.md) | [92.2](/filings/0001437749-26-002599.md) | [91.9](/filings/0001437749-26-014992.md) | [97.4 d](/filings/0001437749-26-027789.md) | | Research and development | $m | not reported | not reported | [15.5](/filings/0001437749-25-014264.md) | not reported | not reported | not reported | [5.4](/filings/0001437749-26-014992.md) | [5.6 d](/filings/0001437749-26-027789.md) | not reported | not reported | [5.6](/filings/0001437749-26-014992.md) | [6.1 d](/filings/0001437749-26-027789.md) | | Selling, general and administrative | $m | [43.6](/filings/0001437749-24-032878.md) | [43.3](/filings/0001437749-25-002393.md) | [41.8](/filings/0001437749-25-014264.md) | [41.0 d](/filings/0001437749-26-027789.md) | [43.0](/filings/0001437749-25-032584.md) | [45.7](/filings/0001437749-26-002599.md) | [52.0](/filings/0001437749-26-014992.md) | [52.6 d](/filings/0001437749-26-027789.md) | [54.4](/filings/0001437749-25-032584.md) | [55.6](/filings/0001437749-26-002599.md) | [52.4](/filings/0001437749-26-014992.md) | [56.9 d](/filings/0001437749-26-027789.md) | | Operating income | $m | [26.9](/filings/0001437749-24-032878.md) | [25.8](/filings/0001437749-25-002393.md) | [21.8](/filings/0001437749-25-014264.md) | [27.1 d](/filings/0001437749-26-027789.md) | [24.1](/filings/0001437749-25-032584.md) | [8.5](/filings/0001437749-26-002599.md) | [26.3](/filings/0001437749-26-014992.md) | [34.7 d](/filings/0001437749-26-027789.md) | [29.6](/filings/0001437749-25-032584.md) | [35.6](/filings/0001437749-26-002599.md) | [90.8](/filings/0001437749-26-014992.md) | [37.6 d](/filings/0001437749-26-027789.md) | | Interest expense | $m | [1.3](/filings/0001437749-24-032878.md) | [1.0](/filings/0001437749-25-002393.md) | [0.9](/filings/0001437749-25-014264.md) | [1.3 d](/filings/0001437749-26-027789.md) | [1.0](/filings/0001437749-25-032584.md) | [5.6](/filings/0001437749-26-002599.md) | [8.4](/filings/0001437749-26-014992.md) | [9.0 d](/filings/0001437749-26-027789.md) | [8.9](/filings/0001437749-25-032584.md) | [7.9](/filings/0001437749-26-002599.md) | [7.3](/filings/0001437749-26-014992.md) | [6.6 d](/filings/0001437749-26-027789.md) | | Income tax | $m | [5.9](/filings/0001437749-24-032878.md) | [5.4](/filings/0001437749-25-002393.md) | [4.3](/filings/0001437749-25-014264.md) | [5.9 d](/filings/0001437749-26-027789.md) | [5.0](/filings/0001437749-25-032584.md) | [0.7](/filings/0001437749-26-002599.md) | [(5.2)](/filings/0001437749-26-014992.md) | [10.6 d](/filings/0001437749-26-027789.md) | [5.2](/filings/0001437749-25-032584.md) | [6.5](/filings/0001437749-26-002599.md) | [14.0](/filings/0001437749-26-014992.md) | [8.5 d](/filings/0001437749-26-027789.md) | | Net income | $m | [18.8](/filings/0001437749-24-032878.md) | [18.9](/filings/0001437749-25-002393.md) | [15.8](/filings/0001437749-25-014264.md) | [19.6 d](/filings/0001437749-26-027789.md) | [18.2](/filings/0001437749-25-032584.md) | [0.9](/filings/0001437749-26-002599.md) | [21.9](/filings/0001437749-26-014992.md) | [14.8 d](/filings/0001437749-26-027789.md) | [15.1](/filings/0001437749-25-032584.md) | [2.1](/filings/0001437749-26-002599.md) | [67.0](/filings/0001437749-26-014992.md) | [20.5 d](/filings/0001437749-26-027789.md) | | Diluted EPS | $ per share | [1.58](/filings/0001437749-24-032878.md) | [1.59](/filings/0001437749-25-002393.md) | [1.33](/filings/0001437749-25-014264.md) | not reported | [1.53](/filings/0001437749-25-032584.md) | [0.07](/filings/0001437749-26-002599.md) | [1.81](/filings/0001437749-26-014992.md) | not reported | [1.25](/filings/0001437749-25-032584.md) | [0.17](/filings/0001437749-26-002599.md) | [5.55](/filings/0001437749-26-014992.md) | not reported | | Basic EPS | $ per share | [1.60](/filings/0001437749-24-032878.md) | [1.60](/filings/0001437749-25-002393.md) | [1.34](/filings/0001437749-25-014264.md) | not reported | [1.54](/filings/0001437749-25-032584.md) | [0.07](/filings/0001437749-26-002599.md) | [1.83](/filings/0001437749-26-014992.md) | not reported | [1.26](/filings/0001437749-25-032584.md) | [0.17](/filings/0001437749-26-002599.md) | [5.56](/filings/0001437749-26-014992.md) | not reported | - Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [127](/filings/0001437749-23-030173.md) | [142](/filings/0001437749-24-002919.md) | [139](/filings/0001437749-24-014596.md) | [154](/filings/0001437749-25-024450.md) | [165](/filings/0001437749-24-032878.md) | [121](/filings/0001437749-25-002393.md) | [110](/filings/0001437749-25-014264.md) | [105](/filings/0001437749-26-027789.md) | [98.7](/filings/0001437749-25-032584.md) | [97.0](/filings/0001437749-26-002599.md) | [104](/filings/0001437749-26-014992.md) | [179](/filings/0001437749-26-027789.md) | | Current assets | $m | [420](/filings/0001437749-23-030173.md) | [436](/filings/0001437749-24-002919.md) | [419](/filings/0001437749-24-014596.md) | [430](/filings/0001437749-25-024450.md) | [447](/filings/0001437749-24-032878.md) | [465](/filings/0001437749-25-002393.md) | [487](/filings/0001437749-25-014264.md) | [481](/filings/0001437749-26-027789.md) | [488](/filings/0001437749-25-032584.md) | [491](/filings/0001437749-26-002599.md) | [483](/filings/0001437749-26-014992.md) | [552](/filings/0001437749-26-027789.md) | | Total assets | $m | [981](/filings/0001437749-23-030173.md) | [1,005](/filings/0001437749-24-002919.md) | [994](/filings/0001437749-24-014596.md) | [1,005](/filings/0001437749-25-024450.md) | [1,038](/filings/0001437749-24-032878.md) | [1,483](/filings/0001437749-25-002393.md) | [1,555](/filings/0001437749-25-014264.md) | [1,567](/filings/0001437749-26-027789.md) | [1,555](/filings/0001437749-25-032584.md) | [1,555](/filings/0001437749-26-002599.md) | [1,527](/filings/0001437749-26-014992.md) | [1,586](/filings/0001437749-26-027789.md) | | Current liabilities | $m | [132](/filings/0001437749-23-030173.md) | [131](/filings/0001437749-24-002919.md) | [122](/filings/0001437749-24-014596.md) | [128](/filings/0001437749-25-024450.md) | [126](/filings/0001437749-24-032878.md) | [138](/filings/0001437749-25-002393.md) | [143](/filings/0001437749-25-014264.md) | [167](/filings/0001437749-26-027789.md) | [170](/filings/0001437749-25-032584.md) | [171](/filings/0001437749-26-002599.md) | [158](/filings/0001437749-26-014992.md) | [230](/filings/0001437749-26-027789.md) | | Long-term debt | $m | [149](/filings/0001437749-23-030173.md) | [149](/filings/0001437749-24-002919.md) | [149](/filings/0001437749-24-014596.md) | [149](/filings/0001437749-25-024450.md) | [149](/filings/0001437749-24-032878.md) | [534](/filings/0001437749-25-002393.md) | [579](/filings/0001437749-25-014264.md) | [553](/filings/0001437749-26-027789.md) | [545](/filings/0001437749-25-032584.md) | [535](/filings/0001437749-26-002599.md) | [473](/filings/0001437749-26-014992.md) | [518](/filings/0001437749-26-027789.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [595](/filings/0001437749-25-002393.md) | [621](/filings/0001437749-25-014264.md) | [619](/filings/0001437749-25-014264.md) | [622](/filings/0001437749-26-027789.md) | [658](/filings/0001437749-26-002599.md) | [656](/filings/0001437749-26-014992.md) | [687](/filings/0001437749-26-014992.md) | [712](/filings/0001437749-26-027789.md) | [708](/filings/0001437749-26-002599.md) | [700](/filings/0001437749-26-014992.md) | [754](/filings/0001437749-26-014992.md) | [755](/filings/0001437749-26-027789.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: not reported - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [16.2](/filings/0001437749-24-032878.md) | [23.6 d](/filings/0001437749-25-002393.md) | [24.4 d](/filings/0001437749-25-014264.md) | [28.5 d](/filings/0001437749-26-027789.md) | [17.6](/filings/0001437749-25-032584.md) | [9.1 d](/filings/0001437749-26-002599.md) | [9.5 d](/filings/0001437749-26-014992.md) | [33.4 d](/filings/0001437749-26-027789.md) | [16.8](/filings/0001437749-25-032584.md) | [20.6 d](/filings/0001437749-26-002599.md) | [11.7 d](/filings/0001437749-26-014992.md) | [40.4 d](/filings/0001437749-26-027789.md) | | Capital expenditure | $m | [4.3](/filings/0001437749-24-032878.md) | [4.2 d](/filings/0001437749-25-002393.md) | [5.2 d](/filings/0001437749-25-014264.md) | [6.5 d](/filings/0001437749-26-027789.md) | [6.7](/filings/0001437749-25-032584.md) | [7.0 d](/filings/0001437749-26-002599.md) | [6.1 d](/filings/0001437749-26-014992.md) | [8.6 d](/filings/0001437749-26-027789.md) | [6.4](/filings/0001437749-25-032584.md) | [7.7 d](/filings/0001437749-26-002599.md) | [5.6 d](/filings/0001437749-26-014992.md) | [5.5 d](/filings/0001437749-26-027789.md) | | Dividends paid | $m | [3.3](/filings/0001437749-24-032878.md) | [3.6 d](/filings/0001437749-25-002393.md) | [3.5 d](/filings/0001437749-25-014264.md) | [3.5 d](/filings/0001437749-26-027789.md) | [3.5](/filings/0001437749-25-032584.md) | [3.8 d](/filings/0001437749-26-002599.md) | [3.8 d](/filings/0001437749-26-014992.md) | [3.8 d](/filings/0001437749-26-027789.md) | [3.8](/filings/0001437749-25-032584.md) | [4.1 d](/filings/0001437749-26-002599.md) | [4.2 d](/filings/0001437749-26-014992.md) | [4.1 d](/filings/0001437749-26-027789.md) | | Share repurchases | $m | [22.2](/filings/0001437749-24-032878.md) | [4.5 d](/filings/0001437749-25-002393.md) | [5.1 d](/filings/0001437749-25-014264.md) | [0.0 d](/filings/0001437749-26-027789.md) | [4.4](/filings/0001437749-25-032584.md) | [5.2 d](/filings/0001437749-26-002599.md) | [0.0 d](/filings/0001437749-26-014992.md) | [0.3 d](/filings/0001437749-26-027789.md) | [3.7](/filings/0001437749-25-032584.md) | [0.1 d](/filings/0001437749-26-002599.md) | [0.0 d](/filings/0001437749-26-014992.md) | [0.6 d](/filings/0001437749-26-027789.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [12.0](/filings/0001437749-23-030173.md) | [11.9](/filings/0001437749-24-002919.md) | [11.9](/filings/0001437749-24-014596.md) | [11.9](/filings/0001437749-24-032878.md) | [11.9](/filings/0001437749-25-002393.md) | [11.8](/filings/0001437749-25-014264.md) | [11.9](/filings/0001437749-25-032584.md) | [12.0](/filings/0001437749-26-002599.md) | [12.1](/filings/0001437749-26-014992.md) | [12.0](/filings/0001437749-25-032584.md) | [12.1](/filings/0001437749-26-002599.md) | [12.1](/filings/0001437749-26-014992.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 12,119,465 at 2026-08-07, from the cover of the [10-K filed 2026-08-14](/filings/0001437749-26-027789.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.